"An excellent fourth quarter with significant growth and pipeline progress"
Fourth quarter and full year summary
October - December
- Total revenues amounted to
SEK 375 (268) million, an increase of 40% (36% at CER1), whereof product sales wereSEK 366 (267) million, an increase of 37% (33% at CER1) - Compared to the previous quarter, product sales increased 6% (7% at CER1)
-
Operating result was
SEK -29 (19) million, a decrease ofSEK 47 million , includingSEK 51 million social security costs accrual in the quarter relating to employee long term incentive programs, driven by the share value increase in the quarter -
Cash at the end of the quarter was
SEK 1,190 (566) million, an increase ofSEK 624 million (110%) - Number of patients treated with Buvidal® increased to approximately 48,000
-
New Drug Application for Oclaiz™ (CAM2029) for the treatment of acromegaly submitted to the
US FDA - Recruitment completed in the SORENTO study of CAM2029 in patients with neuroendocrine tumors
- The guidance for revenue and profit before tax for the full year 2023 was raised in October
-
Nasdaq
Stockholm announces thatCamurus is moved from Mid Cap to Large Cap
January - December
- Total revenues amounted to
SEK 1,717 (956) million, an increase of 80% (72% at CER1), whereof product sales wereSEK 1,299 (935) million, an increase of 39% (34% at CER1) -
Operating result was
SEK 526 (72) million, an increase ofSEK 454 million (631%)
Significant events after the period
Camurus executed a directed share issue raising gross proceeds ofSEK 1,090 million
Full year outlook 2024
- Total revenues
SEK 1,740 to 1,860 million -
Profit before tax
SEK 330 to 450 million
1. At constant exchange rates
"
Audiocast
Financial analysts and media are invited to attend a telephone conference and presentation of the results today at
For more information:
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
About
This information is information that
https://news.cision.com/camurus-ab/r/camurus--full-year-report-2023,c3929043
https://mb.cision.com/Main/13456/3929043/2606107.pdf
(c) 2024 Cision. All rights reserved., source